Theratechnologies Submits sBLA for Trogarzo Intramuscular (IM) Method of Administration to FDA
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies Inc. has submitted a supplemental Biologics License Application (sBLA) to the FDA for an intramuscular (IM) method of administering the maintenance dose of Trogarzo, a treatment for multidrug-resistant HIV-1 infection in adults. The new IM method aims to provide an alternative to the existing intravenous administration.
January 02, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theratechnologies Inc. has filed an sBLA for an IM administration method of Trogarzo, potentially expanding its treatment's accessibility and convenience for patients.
The submission of the sBLA for a new method of administration for Trogarzo could lead to increased usage and improved patient compliance, which may positively impact Theratechnologies' market share and revenues in the short term. The news directly pertains to the company and is critical for investors as it represents a potential growth opportunity in the company's product offering.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100